84 related articles for article (PubMed ID: 28058684)
1. Development and investigation of recombinant immunotoxin protein 4D5scFv-mCherry-PE(40).
Shilova ON; Souslova EA; Pilunov AM; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2016 Nov; 471(1):450-453. PubMed ID: 28058684
[TBL] [Abstract][Full Text] [Related]
2. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.
Mironova KE; Proshkina GM; Ryabova AV; Stremovskiy OA; Lukyanov SA; Petrov RV; Deyev SM
Theranostics; 2013; 3(11):831-40. PubMed ID: 24312153
[TBL] [Abstract][Full Text] [Related]
3. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
[TBL] [Abstract][Full Text] [Related]
4. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
[TBL] [Abstract][Full Text] [Related]
5. [Genetically encoded photoimmunosensitizer].
Serebrovskaia EO; Stremovskiĭ OA; Chudakov DM; Luk'ianov KA; Deev SM
Bioorg Khim; 2011; 37(1):137-44. PubMed ID: 21460889
[TBL] [Abstract][Full Text] [Related]
6. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of targeted HER2-specific phototoxins based on flavoprotein miniSOG is determined by the rate of their internalization.
Shilova ON; Proshkina GM; Ryabova AV; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2017 Jul; 475(1):256-258. PubMed ID: 28864891
[TBL] [Abstract][Full Text] [Related]
8. A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
Zdobnova T; Sokolova E; Stremovskiy O; Karpenko D; Telford W; Turchin I; Balalaeva I; Deyev S
Oncotarget; 2015 Oct; 6(31):30919-28. PubMed ID: 26436696
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors.
Sokolova EA; Stremovskiy OA; Zdobnova TA; Balalaeva IV; Deyev SM
Acta Naturae; 2015; 7(4):93-6. PubMed ID: 26798495
[TBL] [Abstract][Full Text] [Related]
10. Development of a recombinant hCG-specific single chain immunotoxin cytotoxic to hCG expressing cancer cells.
Nand KN; Gupta JC; Panda AK; Jain SK
Protein Expr Purif; 2015 Feb; 106():10-7. PubMed ID: 25448825
[TBL] [Abstract][Full Text] [Related]
11. Highly specific hybrid protein DARPin-mCherry for fluorescent visualization of cells overexpressing tumor marker HER2/neu.
Mironova KE; Chernykh ON; Ryabova AV; Stremovskiy OA; Proshkina GM; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1391-6. PubMed ID: 25716734
[TBL] [Abstract][Full Text] [Related]
12. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
13. The Application of Recombinant Phototoxins 4D5scFv-miniSOG and DARPin-miniSOG to Study the HER2 Receptor Internalization.
Kuzichkina EO; Shilova ON; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2018 Sep; 482(1):245-248. PubMed ID: 30397884
[TBL] [Abstract][Full Text] [Related]
14. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
[TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy.
Cao X; Yu H; Chen C; Wei J; Wang P
Biotechnol Lett; 2015 Jul; 37(7):1347-54. PubMed ID: 25735855
[TBL] [Abstract][Full Text] [Related]
16. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of the cytotoxic action of immunophototoxin 4D5scFV-miniSOG on HER2/neu-positive cancer cells.
Proshkina GM; Mironova KE; Deyev SM; Petrov RV
Dokl Biochem Biophys; 2015; 460():16-9. PubMed ID: 25772982
[No Abstract] [Full Text] [Related]
19. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
20. Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells.
Tang Q; Onitsuka M; Tabata A; Tomoyasu T; Nagamune H
Anticancer Res; 2018 Jul; 38(7):4319-4325. PubMed ID: 29970568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
